FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2565581720> ?p ?o ?g. }

• W2565581720 endingPage "80" @default.
• W2565581720 startingPage "1" @default.
• W2565581720 abstract "Background We previously reported that repeated low-dose grass pollen intradermal allergen injection suppresses allergen-induced cutaneous late-phase responses, comparable with conventional high-dose subcutaneous and sublingual immunotherapy. Objective To evaluate the efficacy and mechanism of grass pollen intradermal immunotherapy for treatment of allergic rhinitis. Design A Phase II, double-blind, randomised controlled parallel-group trial. Setting Single-centre UK study. Participants Adults aged 18–65 years, with grass pollen-induced allergic rhinoconjunctivitis. Interventions Seven 2-weekly intradermal injections were given into the forearm, containing either Phleum pratense soluble grass pollen extract (7 ng of the major allergen Phl p 5) or histamine control. Main outcome measures The primary outcome was a combined symptom and medication score (CSMS) during the 2013 grass pollen season. Secondary clinical outcomes were overall symptom scores; individual symptoms scores for nose, mouth, eyes and lungs; overall medication scores; CSMSs during the peak season; visual analogue scale (VAS) scores for nose and eye symptoms; Mini Rhinitis Quality of Life Questionnaire scores; health-related quality-of-life scores (European Quality of Life-5 Dimensions, 5-levels); a global evaluation of symptoms, number of symptom-free and medication-free days; number of days when prednisolone was used; and adverse events. Mechanistic studies included measurement of late-phase skin response sizes, allergen-specific antibody titres, analysis of skin biopsies and basophil activation tests. Results There was no significant difference in CSMSs between treatment arms [difference in median area under curve (AUC) 14, 95% confidence interval (CI) –172.5 to 215.1; p = 0.80]. Paradoxically, among the secondary outcomes, nasal symptoms measured with daily scores were higher in the active arm (difference in median AUC 35, 95% CI 4.0 to 67.5; p = 0.03), with a trend for higher nasal symptoms measured by VASs (difference in median AUC 53, 95% CI –11.6 to 125.2; p = 0.05). No differences were seen in other clinical outcomes in the main intention-to-treat analysis. In mechanistic studies, active treatment increased P. pratense -, Phl p 1- and Phl p 5-specific immunoglobulin E (all p = 0.001) compared with the control. T cells cultured from skin biopsies of active intradermal immunotherapy subjects showed higher T helper type 2 cell (Th2) marker CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) expression ( p < 0.05) and lower T helper type 1 cell marker CXCR3 [chemokine (C-X-C Motif) receptor 3] expression ( p < 0.05), respectively. Interleukin 5 messenger ribonucleic acid, measured by microarray, was more highly expressed by cultured skin T cells in the active arm ( p < 0.05). Late-phase skin responses to grass pollen were still inhibited up to 7 months after intradermal immunotherapy ( p = 0.03), but not at 10–13 months’ time points. Limitations Grass pollen doses were not increased during the course, as our proof-of-concept trial showed that repeating the same doses was sufficient to achieve almost complete late-response suppression. Injections were not continued throughout the season, as previous subcutaneous grass pollen immunotherapy trials have demonstrated preseasonal regimen efficacy. Conclusions Intradermal immunotherapy suppressed late-phase skin responses to allergen, but was not clinically effective. The intervention appeared to have an immunological priming effect and exacerbated certain seasonal symptoms, notably in the nose. Future work Further studies on low-dose intradermal grass pollen immunotherapy are not recommended because of our demonstrated worsening of allergic rhinitis symptoms and immunological priming. The findings are of great significance for other novel immunotherapies targeting the skin, such as epicutaneous techniques. Trial registration Current Controlled Trials ISRCTN78413121. Funding This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership." @default.
• W2565581720 created "2017-01-06" @default.
• W2565581720 creator A5003426440 @default.
• W2565581720 creator A5008486711 @default.
• W2565581720 creator A5012611835 @default.
• W2565581720 creator A5015577277 @default.
• W2565581720 creator A5015693854 @default.
• W2565581720 creator A5026390715 @default.
• W2565581720 creator A5028378271 @default.
• W2565581720 creator A5028868991 @default.
• W2565581720 creator A5032905040 @default.
• W2565581720 creator A5043192106 @default.
• W2565581720 creator A5056940538 @default.
• W2565581720 creator A5070138379 @default.
• W2565581720 creator A5077658682 @default.
• W2565581720 creator A5087656991 @default.
• W2565581720 date "2016-12-01" @default.
• W2565581720 modified "2023-10-15" @default.
• W2565581720 title "A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis" @default.
• W2565581720 cites W1549303438 @default.
• W2565581720 cites W1556246926 @default.
• W2565581720 cites W1577022278 @default.
• W2565581720 cites W1595485837 @default.
• W2565581720 cites W1601801276 @default.
• W2565581720 cites W1968243444 @default.
• W2565581720 cites W1975797729 @default.
• W2565581720 cites W1976640573 @default.
• W2565581720 cites W1977488181 @default.
• W2565581720 cites W1983600587 @default.
• W2565581720 cites W1986404685 @default.
• W2565581720 cites W1990166011 @default.
• W2565581720 cites W2028803867 @default.
• W2565581720 cites W2041302559 @default.
• W2565581720 cites W2042015803 @default.
• W2565581720 cites W2042555734 @default.
• W2565581720 cites W2043608150 @default.
• W2565581720 cites W2046574729 @default.
• W2565581720 cites W2050905759 @default.
• W2565581720 cites W2053056632 @default.
• W2565581720 cites W2059332672 @default.
• W2565581720 cites W2061178990 @default.
• W2565581720 cites W2063177917 @default.
• W2565581720 cites W2065738222 @default.
• W2565581720 cites W2067136087 @default.
• W2565581720 cites W2093740248 @default.
• W2565581720 cites W2098715405 @default.
• W2565581720 cites W2109347130 @default.
• W2565581720 cites W2111692694 @default.
• W2565581720 cites W2121760095 @default.
• W2565581720 cites W2131276393 @default.
• W2565581720 cites W2133774441 @default.
• W2565581720 cites W2143808455 @default.
• W2565581720 cites W2150725841 @default.
• W2565581720 cites W2153011983 @default.
• W2565581720 cites W2158883866 @default.
• W2565581720 cites W2177575213 @default.
• W2565581720 cites W2554585046 @default.
• W2565581720 cites W4205090341 @default.
• W2565581720 doi "https://doi.org/10.3310/eme03100" @default.
• W2565581720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27977090" @default.
• W2565581720 hasPublicationYear "2016" @default.
• W2565581720 type Work @default.
• W2565581720 sameAs 2565581720 @default.
• W2565581720 citedByCount "1" @default.
• W2565581720 countsByYear W25655817202021 @default.
• W2565581720 crossrefType "journal-article" @default.
• W2565581720 hasAuthorship W2565581720A5003426440 @default.
• W2565581720 hasAuthorship W2565581720A5008486711 @default.
• W2565581720 hasAuthorship W2565581720A5012611835 @default.
• W2565581720 hasAuthorship W2565581720A5015577277 @default.
• W2565581720 hasAuthorship W2565581720A5015693854 @default.
• W2565581720 hasAuthorship W2565581720A5026390715 @default.
• W2565581720 hasAuthorship W2565581720A5028378271 @default.
• W2565581720 hasAuthorship W2565581720A5028868991 @default.
• W2565581720 hasAuthorship W2565581720A5032905040 @default.
• W2565581720 hasAuthorship W2565581720A5043192106 @default.
• W2565581720 hasAuthorship W2565581720A5056940538 @default.
• W2565581720 hasAuthorship W2565581720A5070138379 @default.
• W2565581720 hasAuthorship W2565581720A5077658682 @default.
• W2565581720 hasAuthorship W2565581720A5087656991 @default.
• W2565581720 hasBestOaLocation W25655817201 @default.
• W2565581720 hasConcept C126322002 @default.
• W2565581720 hasConcept C141071460 @default.
• W2565581720 hasConcept C141105273 @default.
• W2565581720 hasConcept C142724271 @default.
• W2565581720 hasConcept C159654299 @default.
• W2565581720 hasConcept C168563851 @default.
• W2565581720 hasConcept C197934379 @default.
• W2565581720 hasConcept C203014093 @default.
• W2565581720 hasConcept C204787440 @default.
• W2565581720 hasConcept C207480886 @default.
• W2565581720 hasConcept C27081682 @default.
• W2565581720 hasConcept C2776949755 @default.
• W2565581720 hasConcept C2777456892 @default.
• W2565581720 hasConcept C2778311950 @default.
• W2565581720 hasConcept C2779787640 @default.
• W2565581720 hasConcept C2780510475 @default.
• W2565581720 hasConcept C44249647 @default.

• next